EN | UA
EN | UA

Help Support

Back

Ruxolitinib cream: An effective therapy for atopic dermatitis across anatomical regions

atopic dermatitis management atopic dermatitis management
atopic dermatitis management atopic dermatitis management

This study examined the effectiveness, safety, and tolerability of Ruxolitinib (selective inhibitor of Janus kinase) cream in specific anatomical regions, particularly focusing on the head/neck lesions, in atopic dermatitis sufferers.

See All

Key take away

Ruxolitinib cream as a standalone treatment shows quick and significant improvement in both the severity and extent of mild to moderate atopic dermatitis across various anatomical regions, including the head and neck, in both adolescents and adults.

Background

This study examined the effectiveness, safety, and tolerability of Ruxolitinib (selective inhibitor of Janus kinase) cream in specific anatomical regions, particularly focusing on the head/neck lesions, in atopic dermatitis sufferers.

Method

This post-hoc analysis utilized pooled data from the eight-week, vehicle-controlled period of the TRuE-AD1 and TRuE-AD2 studies. Researchers examined Eczema Area and Severity Index (EASI) responses in various anatomical regions in a pooled population of 1208 individuals, as well as among those with baseline involvement of the head/neck (n = 663). Furthermore, quality of life measures, itch severity, Investigator's Global Assessment (IGA), and tolerability of the cream at application sites were determined.

Result

By week 2, Ruxolitinib cream illustrated remarkable improvements in EASI scores across all anatomical regions as opposed to the vehicle, with continued enhancements observed through week 8. A substantial proportion of patients with head/neck involvement who used Ruxolitinib cream attained pivotal reductions in itch severity, improvements in IGA, and enhanced quality of life when compared to those using the vehicle. The incidence of application site reactions with Ruxolitinib cream was low (<3%), even among those with head/neck involvement. At the site of application, Ruxolitinib cream was well-tolerated.

Conclusion

The findings of the study endorsed the effectiveness of Ruxolitinib cream for relieving atopic dermatitis across various anatomical regions, including the challenging head/neck area, which often poses challenges in management and considerably hampers the quality of life of the affected patients.

Source:

Journal of Dermatological Treatment

Article:

Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studies

Authors:

Eric L Simpson et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: